What is MannKind?
MannKind Corporation is a specialized biopharmaceutical entity dedicated to the development and commercialization of innovative therapeutic products. The company maintains a robust portfolio, most notably featuring Afrezza Inhalation Powder for glycemic control in diabetic patients and the V-Go wearable insulin delivery device. Furthermore, the firm has expanded its clinical footprint into pulmonary health through the development of Tyvaso DPI, targeting pulmonary arterial hypertension. By focusing on high-need patient populations, MannKind leverages proprietary delivery technologies to address significant gaps in current treatment paradigms, positioning itself as a key player in the intersection of medical device engineering and pharmaceutical science.
How much funding has MannKind raised?
MannKind has raised a total of $1.7B across 14 funding rounds:
Stock Offering
$36.2M
Stock Offering
$47.5M
Stock Offering
$61M
Stock Offering
$28M
Debt
$2M
Stock/Share Issuance
$500M
Stock/Share Issuance
$50M
Stock Issuance/Offering (2015): $36.2M, investors not publicly disclosed
Stock Issuance/Offering (2016): $47.5M, investors not publicly disclosed
Stock Issuance/Offering (2017): $61M, investors not publicly disclosed
Stock Issuance/Offering (2018): $28M, investors not publicly disclosed
Debt (2020): $2M led by PPP
Stock/Share Issuance (2025): $500M, investors not publicly disclosed
Stock/Share Issuance (2026): $50M featuring Frazier Life Sciences Management
Key Investors in MannKind
Sanofi
Sanofi is a global biopharmaceutical company dedicated to improving lives through scientific innovation. The company focuses on discovering, developing, and delivering medicines and vaccines across immunology, rare diseases, neurology, oncology, and preventive care.
Frazier Life Sciences Management
Frazier Life Sciences is a longstanding biotech investment firm that employs both venture and public strategies to partner with and build companies focused on developing novel therapeutics.
Deerfield
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy, supporting companies across the healthcare ecosystem with flexible funding models.
What's next for MannKind?
With the recent capital injection, MannKind is well-positioned to accelerate its commercial reach and refine its operational efficiency. The company's strategic roadmap likely involves scaling the distribution of its core inhalation and infusion technologies while potentially exploring new indications for its existing therapeutic assets. Given the competitive landscape of the orphan lung disease market, the firm will likely prioritize clinical data generation and market access initiatives to drive adoption. This major enterprise-level funding provides the necessary runway to sustain R&D intensity and navigate the regulatory hurdles inherent in the biopharmaceutical industry, ensuring that MannKind remains at the forefront of patient-centric innovation.
See full MannKind company page
